Primary Malignant Neoplasms of the Liver

Sherlock's Diseases of the Liver and Biliary System, 12th Edition

Volumn , Issue , 2011, Pages 681-703

  Sherman, Morris ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer screening; Chemoembolization; Cholangiocarcinoma; Dysplasia; Radiofrequency ablation

Indexed keywords

EID: 84885186865     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341294.ch35     Document Type: Chapter

References (158)

1. El-Serag H, Mason AC. Rising incidence of hepatocellular carcinoma in the United states. N. Eng. J. Med. 1999; 340: 745-750.
2. Okuda K, Fujimoto I, Hanai A et al. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 1987; 47: 4967-4972.
3. Taylor-Robinson SD, Foster GR et al. Increase in primary liver cancer in the UK 1979-1974. Lancet 1997; 350: 1142-1143.
4. Deuffic S, Poynard T, Buffat L et al. Trends in primary liver cancer. Lancet 1998; 351: 214-215.
5. Stroffolini T, Andreone P, Andriulli A et al. Characteristics of hepatocellular carcinoma in Italy. J. Hepatol. 1998; 29: 944-952.
6. Bosch FX, Ribes J, Cléries R et al. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 2005; 9: 191-211.
7. Beasley RP, Hwang LY, Lin CC et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-1133.
8. Sakuma K, Saitoh N, Kasai M et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology 1988; 8: 1642-1646.
9. Villeneuve JP, Desrochers M, Infante-Rivard C et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994 106: 1000-1005.
10. McMahon B J, Alberts SR, Wainwright R B et al. Hepatitis B-related sequelae. Prospective study of 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch. Intern. Med. 1990; 150: 1051-1054.
11. Sherman M, Peltekian K M, Lee C. Screening for hepatocellular carcinoma in chronic carriers of Hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432-438.
12. Fattovich G, Giustina G, Schalm SW et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21: 77-82.
13. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 2: 463-472.
14. Bruix J, Barrera J M, Calvert X et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatitis cirrhosis. Lancet 1989; ii: 1004-1006.
15. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695.
16. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinoma: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
17. Benvegnu L, Fattovich G, Noventa F et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 2442-2448.
18. Cottone M, Turri M, Caltagirone M et al. Screening for hepatocellular carcinoma in patients with Childs A cirrhosis: an 8 year prospective study by ultrasound and alphafetoprotein. J. Hepatol. 1994; 21: 1029-1034.
19. Borzio M, Bruno S, Roncalli M et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis. A prospective study. Gastroenterology 1995; 108: 812-817.
20. Pateron D, Ganne N, Trinchet JC et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J. Hepatol. 1994; 20: 65-71.
21. Colombo M, De Franchis R, Del Ninno E et al. Hepatocellular carcinoma in Italian patients with cirrhosis. Lancet 1991; 325: 675-680.
22. Zaman SN, Melia WM, Johnson RD et al. Risk factors in development of hepatocellular carcinoma in cirrhosis: Prospective study of 613 patients. Lancet 1985; 1: 1357-1360.
23. Fargion S, Fracanzani AL, Piperno A et al. Prognostic factors for hepatocellular carcinoma in genetic haemochromatosis. Hepatology 1994; 20: 1426-1431.
24. Caballeria L, Pares A, Castells A et al. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am. J. Gastroenterol. 2001; 96: 1160-1163.
25. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-298.
26. Ross RK, Yuan JM, Yu MC et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943-946.
27. Umemura T, Ichijo T, Yoshizawa K et al. Epidemiology of hepatocellular carcinoma in Japan. J. Gastroenterol. 2009; 44(Suppl. 19): 102-107.
28. Bosetti C, Levi F, Boffetta P et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008; 48: 137-145.
29. Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin defi-ciency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 2005; 42: 514-521.
30. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-993.
31. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664.
32. Hytiroglou P, Theise ND, Schwartz M et al. Macroregenerative nodules in a series of adult cirrhotic liver explants: issues of classification and nomenclature. Hepatology 1995; 21: 703-708.
33. Roncalli M, Roz E, Coggi G et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 1999; 30: 1174-1178.
34. Arakawa M, Kage M, Sugihara S et al. Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver. Observations in five cases. Gastroenterology 1986; 91: 198-208.
35. Tiniakos DG, Brunt EM. Proliferating cell nuclear antigen and Ki-67 labeling in hepatocellular nodules: a comparative study. Liver 1999; 19: 58-68.
36. Dutta U, Kench J, Byth K et al. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Hum. Pathol. 1998; 29: 1279-1284.
37. Borzio M, Trere D, Borzio F et al. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol. Pathol. 1998; 510: 96-101.
38. Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view. Liver Transpl. 2004; 10(2 Suppl. 1): S3-S8.
39. Nakashima T, Kojiro M. Hepatocellular Carcinoma. Tokyo: Springer Verlag, 1987.
40. Libbrecht L, Severi T, Cassiman D et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am. J. Surg. Pathol. 2006; 30: 1405-1411.
41. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Sem. Liver Dis. 2005; 25: 133-142.
42. Kanda M, Nomoto S, Nishikawa Y et al. Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J. Surg. Oncol. 2008 1; 98: 190-196.
43. Schoenleber SJ, Kurtz DM, Talwalkar JA et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br. J. Cancer 2009; 100: 1385-1392.
44. Breuhahn K, Vreden S, Haddad R et al. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res. 2004; 64: 6058-6064.
45. Lee JS, Chu IS, Heo J et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 667-676.
46. Okabe H, Satoh S, Kato T et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001; 61: 2129-2137.
47. Iizuka N, Oka M, Yamada-Okabe H et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003; 361: 923-929.
48. Llovet JM, Chen Y, Wurmbach E et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758-1767.
49. Nam SW, Lee JH, Noh JH et al. Comparative analysis of expression profiling of early-stage carcinogenesis using nodule-in-nodule-type hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 2006; 18: 239-247.
50. Wurmbach E, Chen YB, Khitrov G et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45: 938-947.
51. Nam SW, Park JY, Ramasamy A et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 2005; 42: 809-818.
52. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 1995-2004.
53. Wing JR, Panz VR, Joffe BI et al. Hypoglycemia in hepatocellular carcinoma: failure of short-term growth hormone administration to reduce enhanced glucose requirements. Metabolism 1991; 40: 508-512.
54. Mahoney EJ, Monchik JM, Donatini G et al. Life-threatening hypercalcemia from a hepatocellular carcinoma secreting intact parathyroid hormone: localization by sestamibi single-photon emission computed tomographic imaging. Endocr. Pract. 2006; 12: 302-306.
55. Ryu T, Nishimura S, Miura H et al. Thrombopoietin-producing hepatocellular carcinoma. Intern. Med. 2003; 42: 730-734.
56. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004; 130: 417-422.
57. Thompson Coon J, Rogers G, Hewson P et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br. J. Cancer 2008; 98: 1166-1175.
58. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am. J. Med. 1996; 101: 422-434.
59. Arguedas MR, Chen VK, Eloubeidi MA et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am. J. Gastroenterol. 2003; 98: 679-690.
60. Patel D, Terrault NA, Yao FY et al. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin. Gastroenterol. Hepatol. 2005; 3: 75-84.
61. Lin OS, Keeffe EB, Sanders GD et al. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment. Pharmacol. Ther. 2004; 19: 1159-1172.
62. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
63. Trevisani F, D'Intino PE, Morselli-Labate AM et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 2001; 34: 570-575.
64. Pateron D, Ganne N, Trinchet JC et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J. Hepatol. 1994; 20: 65-71.
65. Marrero JA, Su GL, Wei W et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37: 1114-1121.
66. Durazo FA, Blatt LM, Corey WG et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2008; 23: 1541-1548.
67. Sterling RK, Jeffers L, Gordon F et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2009; 7: 104-113.
68. Miyaaki H, Nakashima O, Kurogi M et al. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J. Gastroenterol. 2007; 42: 962-968.
69. Carr BI, Kanke F, Wise M et al. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig. Dis. Sci. 2007; 52: 776-782.
70. Taouli B, Goh JS, Lu Y et al. Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. J. Comput. Assist. Tomogr. 2005; 29: 425-429.
71. O'Malley ME, Takayama Y, Sherman M. Outcome of small (10-20 mm) arterial phase-enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease. Am. J. Gastroenterol. 2005; 100: 1523-1528.
72. Sala M, Llovet JM, Vilana R et al; Barcelona Clínic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352-1360.
73. Nathan H, Schulick RD, Choti MA et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann. Surg. 2009; 249: 799-805.
74. Trevisani F, De NS, Rapaccini G et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am. J. Gastroenterol. 2002; 97: 734-744.
75. Santagostino E, Colombo M, Rivi M et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003; 102: 78-82.
76. Kim DY, Han KH, Ahn SH et al. Semiannual surveillance for hepatocellular carcinoma improved patient survival compared to annual surveillance (Korean experience). Hepatology 2007; 46(Suppl. 1)403A.
77. Nicolau C, Vilana R, Catalá V et al. I mportance of evaluating all vascular phases on contrast-enhanced sonography in the differentiation of benign from malignant focal liver lesions. AJR Am. J. Roentgenol. 2006; 186: 158-167.
78. Iannaccone R, Laghi A, Catalano C et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology 2005; 234: 460-467.
79. Torzilli G, Minagawa M, Takayama T et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999; 30: 889-893.
80. Bremner KE, Bayoumi AM, Sherman M et al. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can. J. Gastroenterol. 2007; 21: 491-500.
81. Burrel M, Llovet JM, Ayuso C et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation. Hepatology 2003; 38: 1034-1042.
82. Jeong YY, Mitchell DG, Kamishima T. Small(< 20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. AJR Am. J. Roentgenol. 2002; 178: 1327-1334.
83. Fracanzani AL, Burdick L, Borzio M et al. Contrast-enhanced doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology 2001; 34: 1109-1112.
84. Takayama T, Makuuchi M, Hirohashi S et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990; 336: 1150-1153.
85. Stigliano R, Marelli L, Yu D et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat. Rev. 2007; 33: 437-447.
86. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19: 329-338.
87. Sharma P, Harper AM, Hernandez JL et al. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am. J. Transplant. 2006; 6: 1957-1962.
88. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-755.
89. Vauthey JN, Lauwers GY, Esnaola NF et al. Simplified staging for hepatocellular carcinoma. J. Clin. Oncol. 2002; 20: 1527-1536.
90. Leung TW, Tang AM, Zee B et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-1769.
91. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009; 29: 502-510.
92. Fong Y, Sun RL, Jarnagin W et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann. Surg. 1999; 229: 790-799.
93. Grazi GL, Ercolani G, Pierangeli F et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann. Surg. 2001; 234: 71-78.
94. Bruix J, Castells A, Bosch J et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-1022.
95. Ishikawa M, Yogita S, Miyake H et al. Clarification of risk factors for hepatectomy in patients with hepatocellular carcinoma. Hepatogastroenterology 2002; 49: 1625-1631.
96. Ishizawa T, Hasegawa K, Aoki T et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916.
97. Le Treut YP, Hardwigsen J, Ananian P et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J. Gastrointest. Surg. 2006; 10: 855-862.
98. Okada S, Shimada K, Yamamoto J et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994; 106: 1618-1624.
99. Shirabe K, Kanematsu T, Matsumata T et al. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991; 14: 802-805.
100. Adachi E, Maeda T, Matsumata T et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995; 108: 768-775.
101. Poon RT, Fan ST, Lo CM et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann. Surg. 1999; 229: 216-222.
102. Palavecino M, Chun YS, Madoff DC et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009; 145: 399-405.
103. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996; 334: 693-699.
104. Figueras J, Jaurrieta E, Valls C et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997; 25: 1485-1489.
105. Mazzaferro V, Llovet JM, Miceli R et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009; 10: 35-43.
106. Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-1440.
107. Heckman JT, Devera MB, Marsh JW et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann. Surg. Oncol. 2008; 15: 3169-3177.
108. Graziadei IW, Sandmueller H, Waldenberger P et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003; 9: 557-563.
109. Strong RW, Lynch SV, Ong TH et al. Successful liver transplantation from a living donor to her son. N. Engl. J. Med. 1990; 322: 1505-1507.
110. Kawasaki S. Living-donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 2002; 49: 53-55.
111. Gondolesi GE, Roayaie S, Munoz L et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann. Surg. 2004; 239: 142-149.
112. Sarasin FP, Majno PE, Llovet JM et al. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 2001; 33: 1073-1079.
113. Livraghi T, Bolondi L, Lazzaroni S et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 1992; 69: 925-929.
114. Vilana R, Bruix J, Bru C et al. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16: 353-357.
115. Huang GT, Lee PH, Tsang YM et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann. Surg. 2005; 242: 36-42.
116. Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47: 82-89.
117. Germani G, Pleguezuelo M, Curusamy K et al. Clinical outcomes of radiogrequncy ablation, percutaneous alcohol, and acetic acid injection for hepatocellular carcinoma. J. Hepatol. 2010; 52: 380-388.
118. Lencioni RA, Allgaier HP, Cioni D et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240.
119. Lin SM, Lin CJ, Lin CC et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004; 127: 1714-1723.
120. Livraghi T, Solbiati L, Meloni MF et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-451.
121. Pleguezuelo M, Marelli L, Missier M et al. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev. Anti Cancer Ther. 2008; 8: 1623-1644.
122. Llovet JM, Real MI, Montanya X et al. Arterial embolization, chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359: 1734-1739.
123. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresect able hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
124. GETCH. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N. Engl. J. Med. 1995; 332: 1256-1261.
125. Lammer J, Malagari K, Vogl T et al; On Behalf of the PRECISION V Investigators. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. Cardiovasc. Intervent. Radiol. 2009; 33: 41-52.
126. Chang JM, Tzeng WS, Pan HB et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 1994; 74: 2449-2453.
127. Kawai S, Okamura J, Ogawa M et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma-a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother. Pharmacol. 1992; 31 (Suppl.): S1-6.
128. Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma-which technique is more effective. Cardiovasc. Intervent. Radiol. 2007; 30: 6-25.
129. Gish RG, Porta C, Lazar L et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J. Clin. Oncol. 2007; 25: 3069-3075.
130. Yeo W, Mok TS, Zee B et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/ doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst. 2005; 97: 1532-1538.
131. Becker G, Allgaier HP, Olschewski M et al; HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007; 45: 9-15.
132. Llovet JM, Sala M, Castells L et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31: 54-58.
133. Llovet JM, Ricci S, Mazzaferro V et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-390.
134. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
135. Salem R, Lewandowski RJ, Mulcachy MF et al. Radioembolisation for Hepatocellular Carcinoma using Yitrium 90 microspheres: a comprehensive report of long term outcomes. Gastroenterology 2010; 138: 52-64.
136. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 1353-1357.
137. Shaib YH, El-Serag HB, Davila JA et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-626.
138. Taylor-Robinson SD, Toledano MB, Arora S et al. Increase inmortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-20.
139. Parkin DM, Srivatanakul P, Khlat M et al. Liver cancer in Thailand I: a case-control study of cholangiocarcinoma. Int. J. Cancer 1991; 48: 323-28.
140. Chalasani N, Baluyut A, Ismail A et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter casecontrol study. Hepatology 2000; 31: 7-11.
141. Sorensen HT, Friis S, Olsen JH et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998; 28: 921-25.
142. Boberg KM, Schrumpf E, Bergquist A et al. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J. Hepatol. 2000; 32: 374-380.
143. Goydos JS, Brumfield AM, Frezza E et al. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann. Surg. 1998; 227: 398-404.
144. Yokomuro S, Tsuji H, Lunz JG 3rd et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 2000; 32: 26-35.
145. Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin. Liver Dis. 2004; 24: 139-154.
146. Madariaga JR, Iwatsuki S, Todo S et al. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann. Surg. 1998; 227: 70-79.
147. Ohtsuka M, Ito H, Kimura F et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br. J. Surg. 2002; 89: 1525-1531.
148. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69: 1633-1637.
149. Alberts SR, Gores GJ, Kim GP et al. Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin. Proc. 2007; 82: 628-637.
150. Craig JR, Peters RL, Edmondson HA et al. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 1980; 46: 372-379.
151. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004; 39: 798-803.
152. Komuta M, Spee B, Vander Borght S et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008; 47: 1544-1556.
153. Kato I, Kido C. Increased risk of death in thorotrast-exposed patients during the late follow-up period. Jpn J. Cancer Res. 1987; 78: 1187-1192.
154. Ward E, Boffetta P, Andersen A et al. Update of the follow-up of mortality and cancer incidence among European workers employed in the vinyl chloride industry. Epidemiology 2001; 12: 710-718.
155. Falk H, Herbert J, Crowley S et al. Epidemiology of hepatic angiosarcoma in the United States: 1964-1974. Environ. Health Perspect. 1981; 41: 107-113.
156. Popper H, Maltoni C, Selikoff IJ. Vinyl chloride-induced hepatic lesions in man and rodents. A comparison. Liver 1981; 1: 7-20
157. Uchimura K, Nakamuta M, Osoegawa M et al. Hepatic epithelioid hemangioendothelioma. J. Clin. Gastroenterol. 2001; 32: 431-434.
158. Lerut JP, Orlando G, Adam R et al. The place of liver transplantation in the treatment of hepatic epitheloid haemangioendothelioma: report of the European Liver Transplant Registry. Ann. Surg. 2007; 246: 949-957.